法院裁定，维持2023年关于故意侵权的判决，同时要求Guardant Health公司就其11项产品及服务所产生的销售额，向Twinstrand支付6%的特许权使用费。
这一裁决意味着，Twinstrand在知识产权纠纷中取得了关键性胜利。法院不仅确认了此前的侵权认定，还进一步明确了经济补偿的具体数额——按相关产品与服务总销售额的6%计算。
对于Guardant Health而言，这项决定无疑构成了财务上的重大负担。该公司涉及的11项产品与服务，其销售收益将面临持续性的分成义务。裁决结果可能影响其未来的定价策略及市场布局。
Twinstrand方面则对这一结果表示认可。该裁决巩固了其技术专利的有效性，并为公司带来了可预期的长期收益流。法律程序的推进，为该案画上了一个阶段性的句号。
值得注意的是，法院对“故意侵权”的认定具有特殊的法律意义，这通常意味着侵权方明知故犯，因而可能面临更为严苛的赔偿标准。此次6%特许权使用费的设定，亦反映了法院对此类行为的态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.